usa.net Background Different amyotrophic lateral sclerosis (ALS) phenotypes have been recognised ... Objective To define the epidemiology and outcome of ALS phenotypes in a population based setting.

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Dozens of people in one North Carolina family all have amyotrophic lateral sclerosis, a deadly disease with no cure that is ...

Multiple sclerosis can cause neurological changes like weakness and decreased coordination and balance. Changes in the way your body moves may increase the risk of conditions like plantar fasciitis.

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis in which you experience relapses of the disease with periods of remission occurring in between. Relapsing-remitting multiple ...

ndcn.ox.ac.uk Objective To use an unbiased method to test a previously reported association between cerebral arteriovenous malformation (AVM) embolisation and the subsequent development of amyotrophic ...

Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.